# RTA 408 Ophthalmic Suspension for the Treatment of Ocular Inflammation and Pain Following Ocular Surgery

> **NCT02065375** · PHASE2 · COMPLETED · sponsor: **Biogen** · enrollment: 109 (actual)

## Conditions studied

- Inflammation and Pain Following Ocular Surgery

## Interventions

- **DRUG:** Omaveloxolone Ophthalmic Suspension 1.0%
- **DRUG:** Omaveloxolone Opthalmic Suspension 0.5%
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02065375
- **Lead sponsor:** Biogen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-02-28
- **Primary completion:** 2014-09-30
- **Final completion:** 2014-09-30
- **Target enrollment:** 109 (ACTUAL)
- **Last updated:** 2025-06-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02065375

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02065375, "RTA 408 Ophthalmic Suspension for the Treatment of Ocular Inflammation and Pain Following Ocular Surgery". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02065375. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*